These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28878083)

  • 21. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
    Sacks D; Wiehe K; Morris L; Moore PL
    J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T follicular helper cells and HIV/SIV-specific antibody responses.
    Petrovas C; Koup RA
    Curr Opin HIV AIDS; 2014 May; 9(3):235-41. PubMed ID: 24670319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens.
    Ganti RS; Chakraborty AK
    Phys Rev E; 2021 May; 103(5-1):052408. PubMed ID: 34134229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tfh1 Cells in Germinal Centers During Chronic HIV/SIV Infection.
    Velu V; Mylvaganam G; Ibegbu C; Amara RR
    Front Immunol; 2018; 9():1272. PubMed ID: 29928280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating CXCR5
    Martin-Gayo E; Cronin J; Hickman T; Ouyang Z; Lindqvist M; Kolb KE; Schulze Zur Wiesch J; Cubas R; Porichis F; Shalek AK; van Lunzen J; Haddad EK; Walker BD; Kaufmann DE; Lichterfeld M; Yu XG
    JCI Insight; 2017 Jan; 2(2):e89574. PubMed ID: 28138558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
    Doria-Rose NA; Bhiman JN; Roark RS; Schramm CA; Gorman J; Chuang GY; Pancera M; Cale EM; Ernandes MJ; Louder MK; Asokan M; Bailer RT; Druz A; Fraschilla IR; Garrett NJ; Jarosinski M; Lynch RM; McKee K; O'Dell S; Pegu A; Schmidt SD; Staupe RP; Sutton MS; Wang K; Wibmer CK; Haynes BF; Abdool-Karim S; Shapiro L; Kwong PD; Moore PL; Morris L; Mascola JR
    J Virol; 2016 Jan; 90(1):76-91. PubMed ID: 26468542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection.
    Miles B; Miller SM; Connick E
    Front Immunol; 2016; 7():659. PubMed ID: 28082992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
    Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
    Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
    Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design.
    Brenna E; McMichael AJ
    DNA Cell Biol; 2022 Jan; 41(1):38-42. PubMed ID: 34664991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery.
    Thornhill JP; Fidler S; Klenerman P; Frater J; Phetsouphanh C
    Front Immunol; 2017; 8():46. PubMed ID: 28194154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCL13 is a plasma biomarker of germinal center activity.
    Havenar-Daughton C; Lindqvist M; Heit A; Wu JE; Reiss SM; Kendric K; Bélanger S; Kasturi SP; Landais E; Akondy RS; McGuire HM; Bothwell M; Vagefi PA; Scully E; ; Tomaras GD; Davis MM; Poignard P; Ahmed R; Walker BD; Pulendran B; McElrath MJ; Kaufmann DE; Crotty S
    Proc Natl Acad Sci U S A; 2016 Mar; 113(10):2702-7. PubMed ID: 26908875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 infected humanized DRAGA mice develop HIV-specific antibodies despite lack of canonical germinal centers in secondary lymphoid tissues.
    Ollerton MT; Folkvord JM; Peachman KK; Shashikumar S; Morrison EB; Jagodzinski LL; Peel SA; Khreiss M; D'Aquila RT; Casares S; Rao M; Connick E
    Front Immunol; 2022; 13():1047277. PubMed ID: 36505432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
    Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques.
    Sarkar S; Spencer DA; Barnette P; Pandey S; Sutton WF; Basu M; Burch RE; Cleveland JD; Rosenberg AF; Rangel-Moreno J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
    Front Immunol; 2021; 12():757811. PubMed ID: 34745131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.